Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Bristol-Myers Squibb Company
Bristol-Myers Squibb Company News
Apr 16, 2025 - businesswire.com
2SEVENTY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of 2seventy bio, Inc. - TSVT
Apr 16, 2025 - zacks.com
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?
Bristol-Myers Squibb Company Quantitative Score

About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Bristol-Myers Squibb Company Earnings & Revenue
Bristol-Myers Squibb Company Financials
Table Compare
Compare BMY metrics with: | |||
---|---|---|---|
Earnings & Growth | BMY | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | BMY | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | BMY | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | BMY | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Bristol-Myers Squibb Company Income
Bristol-Myers Squibb Company Balance Sheet
Bristol-Myers Squibb Company Cash Flow
Bristol-Myers Squibb Company Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Buy |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Bristol-Myers Squibb Company Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 2.4400 |
Payment Date | Dividend | Frequency |
---|---|---|
2025-05-01 | 0.62 | Quarterly |
2025-02-03 | 0.62 | Quarterly |
2024-11-01 | 0.6 | Quarterly |
2024-08-01 | 0.6 | Quarterly |
2024-05-01 | 0.6 | Quarterly |
Bristol-Myers Squibb Company Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
Bristol-Myers Squibb Company Executives
Name | Role |
---|---|
Dr. Christopher S. Boerner Ph.D. | Chief Executive Officer & Chairman |
Ms. Sandra Leung Esq. | Executive Vice President & General Counsel |
Mr. Samit Hirawat M.D. | Executive Vice President, Chief Medical Officer & Head of Development |
Mr. David V. Elkins | Executive Vice President & Chief Financial Officer |
Ms. Karin Shanahan | Executive Vice President of Global Product Development & Supply |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Dr. Christopher S. Boerner Ph.D. | Chief Executive Officer & Chairman | 1971 | 5.14M | |
Ms. Sandra Leung Esq. | Executive Vice President & General Counsel | Female | 1961 | 3.05M |
Mr. Samit Hirawat M.D. | Executive Vice President, Chief Medical Officer & Head of Development | Male | 1969 | 2.97M |
Mr. David V. Elkins | Executive Vice President & Chief Financial Officer | Male | 1968 | 2.93M |
Ms. Karin Shanahan | Executive Vice President of Global Product Development & Supply | Female | 1965 | 2.42M |
Bristol-Myers Squibb Company Insider Trades
Date | 1 Apr |
Name | Shanahan Karin |
Role | EVP, Glob. Prod. Dev. & Supply |
Transaction | Acquired |
Type | M-Exempt |
Shares | 3306 |
Date | 1 Apr |
Name | Shanahan Karin |
Role | EVP, Glob. Prod. Dev. & Supply |
Transaction | Disposed |
Type | F-InKind |
Shares | 1692 |
Date | 1 Apr |
Name | Shanahan Karin |
Role | EVP, Glob. Prod. Dev. & Supply |
Transaction | Disposed |
Type | M-Exempt |
Shares | 3306 |
Date | 31 Mar |
Name | YALE PHYLLIS R |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 573.865 |
Date | 31 Mar |
Name | Samuels Theodore R. II |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 819.807 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
1 Apr | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Acquired | M-Exempt | 3306 |
1 Apr | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Disposed | F-InKind | 1692 |
1 Apr | Shanahan Karin | EVP, Glob. Prod. Dev. & Supply | Disposed | M-Exempt | 3306 |
31 Mar | YALE PHYLLIS R | Director | Acquired | A-Award | 573.865 |
31 Mar | Samuels Theodore R. II | Director | Acquired | A-Award | 819.807 |